Pemvidutide

Pemvidutide is Altimmune's once-weekly injectable that hits two hormone receptors at once at a balanced 1:1 ratio: GLP-1, which curbs appetite, and glucagon, which pushes up energy burn and liver fat metabolism [7]. The IMPACT Phase 2b trial in metabolic dysfunction-associated steatohepatitis, or MASH, delivered positive 24-week histology data published in The Lancet in 2025 [1], followed by 48-week non-invasive fibrosis benefit reported in December 2025 [8]. Pemvidutide holds FDA Breakthrough Therapy Designation in MASH and Fast Track designations in both MASH and alcohol use disorder [9][11]. The PERFORMA Phase 3 MASH trial was initiated on August 3, 2026 [10]. Altimmune must now execute against Novo Nordisk, Eli Lilly, and Boehringer Ingelheim, all of whom are pushing incretin-based drugs into the same MASH and obesity space. Altimmune is essentially a single-asset story, and pemvidutide is the asset.

Pemvidutide is a novel peptide, never approved anywhere. As of August 2026 the asset is in Phase 3 for MASH via the PERFORMA trial (initiated August 3, 2026 [10]) and remains in Phase 2 across three parallel indications: obesity, alcohol-associated liver disease (ALD), and alcohol use disorder (AUD). IMPACT (NCT05989711), the 212-patient Phase 2b MASH trial, reported 24-week biopsy-confirmed histology in The Lancet in 2025 [1] and 48-week topline results in December 2025 showing statistically significant improvements over placebo on non-invasive fibrosis measures (Enhanced Liver Fibrosis and Liver Stiffness Measurement) at both dose arms [8]. RESTORE (NCT07009860) in ALD is active but no longer recruiting, and RECLAIM (NCT06987513) in AUD in patients with obesity has completed enrollment. A separate 24-week MASLD study was published in JHEP Reports in 2025 [2]. Regulatory posture is favorable: FDA Breakthrough Therapy Designation in MASH (December 2025) [9] and Fast Track designations in both MASH and AUD [11]. Cash position removes the near-term financing overhang: Altimmune reported $519M in cash, cash equivalents, and investments as of June 30, 2026 [13], with quarterly cash burn averaging roughly $22-24M [13], sufficient by management guidance to fund operations through the PERFORMA 52-week MASH readout targeted for 2029. Near-term catalysts are PERFORMA design/execution milestones, the RESTORE ALD liver stiffness readout, and obesity Phase 3 initiation. A commercial partnership is no longer a financing necessity but remains a meaningful value catalyst.

GLP-1 and glucagon are two hormones released by the gut and pancreas that do opposite things to blood sugar but similar things to body weight. GLP-1 (glucagon-like peptide 1) tells the brain you are full, slows stomach emptying, and boosts insulin release. Glucagon does the opposite for blood sugar, raising it, but also revs up the liver to burn fat and increases resting energy expenditure. A drug that hits both receptors at once should get you weight loss like a pure GLP-1 (the semaglutide and tirzepatide territory) plus extra fat burning and a specific push on liver fat clearance from the glucagon side. That is the pitch. The mechanism is well validated at the target level. GLP-1 receptor agonism is one of the best-validated drug mechanisms in medicine, backed by more than a decade of Type 2 diabetes and obesity outcomes data across semaglutide, liraglutide, dulaglutide, and tirzepatide (dual GLP-1/GIP). Glucagon receptor (GCGR) is a G-protein coupled receptor on liver cells and adipose tissue whose primary job is regulating hepatic glucose output and lipid handling [4]. The dual-agonist concept has clinical precedent: Boehringer Ingelheim and Zealand Pharma's survodutide produced strong Phase 2 MASH signals, and Merck's efinopegdutide showed liver fat reduction. AstraZeneca's cotadutide was shelved. Altimmune describes pemvidutide as a balanced 1:1 GLP-1/glucagon dual agonist [7], distinct from survodutide's more GLP-1-weighted profile; head-to-head potency ratio disclosures at the receptor level have not been published, so the differentiation claim rests on the balanced-design assertion rather than a peer-reviewed ratio comparison.

IMPACT (NCT05989711) is the anchor. It enrolled 212 adults with biopsy-confirmed MASH and stage F2 or F3 fibrosis, randomized 1:2:2 to weekly pemvidutide 1.2 mg, pemvidutide 1.8 mg, or placebo for 48 weeks. The primary endpoint was NASH resolution (NAS, the NAFLD Activity Score, a 0-8 biopsy grading system for steatosis, ballooning, and lobular inflammation; resolution defined as ballooning zero and lobular inflammation zero or one, plus at least a 2-point NAS reduction) without worsening of fibrosis on paired biopsy [1]. Placebo-controlled and biopsy-anchored, matching current FDA guidance for MASH accelerated approval. The 24-week results published in The Lancet showed statistically significant NASH resolution at both active doses versus placebo. Mean body weight reduction was 5.0% at the 1.2 mg dose and 6.2% at the 1.8 mg dose versus 1.0% for placebo (p<0.001 both doses) [1][12]. Fibrosis improvement on paired biopsy at 24 weeks did not reach significance, which is expected for a 24-week fibrosis endpoint. At 48 weeks Altimmune reported that the composite of a ≥0.5 reduction in ELF and a ≥30% reduction in LSM was achieved by 27.8% (1.2 mg) and 32.4% (1.8 mg) of patients versus 3.2% for placebo [8]. Weight loss at 1.8 mg continued through 48 weeks with no plateau [8]. VCTE (Vibration-Controlled Transient Elastography) is a non-invasive ultrasound-based liver stiffness scan; MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease) is the renamed umbrella term of which MASH is the severe, inflamed subtype. Enrollment finished cleanly. There is no active comparator arm against another incretin, so IMPACT cannot answer the head-to-head question of whether pemvidutide's glucagon component adds anything on top of semaglutide or tirzepatide alone. That gap will follow into Phase 3. RESTORE (NCT07009860) in ALD enrolled 121 patients with a primary endpoint of liver stiffness reduction on VCTE. RECLAIM (NCT06987513) in AUD used heavy-drinking days as its primary endpoint, a validated FDA endpoint for AUD trials. Both are exploratory-scale Phase 2s designed to open new indications, not to support registration on their own. PERFORMA (initiated August 3, 2026) is the pivotal Phase 3 MASH trial, a global, randomized, double-blind, placebo-controlled study with a 52-week readout targeted for 2029 [10][13].

Our model estimates a 8% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 35%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual; it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk sits primarily with the paired-biopsy fibrosis endpoint in the Phase 3 PERFORMA trial. Non-invasive fibrosis benefit at 48 weeks in IMPACT is encouraging [8] but biopsy-confirmed fibrosis improvement without worsening of steatohepatitis is what FDA accelerated approval requires. Resmetirom cleared that bar. Semaglutide's ESSENCE Phase 3 has cleared it as well. Pemvidutide has to. Safety risk is dominated by tolerability and body composition. All GLP-1 based drugs produce nausea, vomiting, and discontinuations. The glucagon arm adds a potential heart rate signal and lipid effects. Pemvidutide has shown LDL cholesterol reductions, which is favorable, but glucagon agonists have historically produced transient transaminase elevations that regulators watch closely in liver-disease populations. Muscle and lean-mass loss is a growing area of scrutiny for the whole incretin class, with a 2025 review making the case that regulators may soon require formal DEXA or functional muscle measurements in obesity trials [5]. Execution risk is meaningfully reduced by cash position. Altimmune reported $519M in cash, cash equivalents, and investments as of June 30, 2026, against quarterly cash burn averaging roughly $22-24M [13]. That is approximately 20+ quarters of runway at current burn, though PERFORMA-driven R&D spend will materially accelerate that burn. Management has publicly guided that cash is sufficient through the PERFORMA 52-week readout targeted for 2029 [13]. A MASH Phase 3 program of PERFORMA's scale plausibly runs $250-400M based on comparable disclosures (Madrigal drew a $250M term loan to support resmetirom development through MAESTRO-NASH readout [14]). Financing risk therefore shifts from existential to marginal: if PERFORMA extends or an obesity Phase 3 is added, dilution or partnership becomes more likely. Commercial risk is the hardest. Even with clean Phase 3 data, pemvidutide would launch into a MASH market where Rezdiffra is entrenched as first-line oral therapy and where Novo's semaglutide and Lilly's tirzepatide can be prescribed off-label on the strength of their own MASH data. Payer access without a differentiated head-to-head will be a fight.

Watch closely. Pemvidutide has moved past the highest-risk data catalyst (48-week IMPACT), received Breakthrough Therapy Designation in MASH, initiated PERFORMA Phase 3, and holds enough cash to reach the 52-week PERFORMA readout without a forced partnership. That is a materially different profile from a typical single-asset small-cap biotech going into Phase 3. The specific data points to watch, in order: (1) PERFORMA enrollment pace and first interim safety looks, since MASH Phase 3 execution is where programs die from operational rather than efficacy failure; (2) an obesity Phase 3 initiation decision and design, following the completed End-of-Phase 2 meeting with FDA for obesity; (3) RESTORE ALD liver stiffness readout, which if positive opens a differentiated indication where the incumbent obesity giants are not yet playing; (4) any large-cap partnership announcement, which would validate the asset commercially even though it is no longer required to fund the pivotal. Check back after each 8-K filing from Altimmune (NASDAQ: ALT). The 2026 10-K filing will be the next natural annual checkpoint for cash runway, PERFORMA guidance, and obesity Phase 3 status [6]. The interesting question about pemvidutide is not whether it works in MASH, the Phase 2b data at both 24 and 48 weeks says it probably does, but whether Altimmune can commercialize it against Novo and Lilly, both of whom will have GLP-1 monotherapy MASH data by the time pemvidutide reads out Phase 3. The bull case is a partnership with a big metabolic-franchise player. The bear case is a small biotech running a $250-400M Phase 3 into a market its rivals will dominate on brand alone.